Tests SGR-1505 in adults with B-cell lymphoma and related blood cancers
Tests the drug SGR-1505 for safety in adults with B-cell blood cancers.
Plain-language title generated from the registry record
Registry title: Study of SGR-1505 in Mature B-Cell Neoplasms
Key facts
- Where
- Chisinau, MoldovaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed mature B-cell cancer that can be measured and needs treatment. It tests the safety and dose of SGR-1505.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Mature B-cell cancer (history confirmed by tissue or cell tests) with measurable or detectable disease that meets criteria for starting treatment.
Main reasons for not taking part
- Needs immediate treatment to reduce tumour size (unless no other treatment choice with potential benefit remains)
- Another invasive cancer in the last 2 years
- Known allergy to SGR-1505 or its other ingredients
- Symptomatic or active disease in the brain or spinal cord (CNS)
- Other illness or finding that would raise the risk of an investigational drug
Read by machine on 12 November 2026.
Where in Moldova
- Institute of Oncology, ARENSIA Exploratory MedicineChisinau, MoldovaContact: Vasile Musteata, MD, PhD (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Schrödinger, Inc.
- Trial code
- NCT05544019EU 2023-505204-34-00
- Record updated
- 13 February 2026
- Original description
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.Read full original descriptionShow less
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Inclusion: Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy; Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Life expectancy ≥ 12 weeks.
Exclusion: The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit); Subject has previous invasive malignancy in the last 2 years; Subject has a known allergy to SGR-1505 or excipients of SGR-1505; Subject has symptomatic or active CNS involvement of disease; Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.